M. Schlesner

Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

This study identifies oncofetal reprogramming in juvenile myelomonocytic leukemia, linking RAS-pathway activation to fetal gene expression and revealing CD52 as a therapeutic target.

RBM39 shapes innate immunity through transcriptional and splicing control of key factors of the interferon response

This study identifies RBM39 as a regulator of innate immunity by controlling transcription and splicing of key interferon response factors, revealing its potential as a therapeutic target.

A connectivity signature for glioblastoma

This paper establishes and validates a connectivity signature in glioblastoma using scRNA-Seq data, showing high connectivity correlates with poor patient survival and specific molecular subtypes.

Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoids.

This study uses patient-derived PDAC organoids to integrate genomic, transcriptomic, and drug response data, identifying novel biomarkers and resistance mechanisms for personalized treatment.

Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

This study characterizes intra-tumor heterogeneity across 2,658 human cancer genomes, identifying subclonal mutations and evolutionary patterns across 38 cancer types.

Reprogramming of stromal fibroblasts by chemotherapy-induced secretion of IFNβ1 drives re-growth of breast cancer cells after treatment.

This study shows chemotherapy-induced IFNβ1 secretion by cancer cells reprograms stromal fibroblasts, promoting breast cancer recurrence through an anti-viral state and pro-inflammatory cytokine expression.

Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level

This study examines intratumor heterogeneity in B cell lymphomas by analyzing transcriptional, genetic, and drug response profiles across malignant subclones and immune cells.

The evolutionary history of 2,658 cancers

This study uses whole-genome sequencing of cancer samples to reconstruct the evolutionary history of 39 cancer types, identifying early and late-stage mutational patterns and driver genes.

Resolving Drug Effects In Patient-Derived Cancer Cells Links Organoid Responses To Genome Alterations

The paper compares drug responses in ovarian cancer organoids and monolayer cultures, finding differences in drug efficacy and genomic associations.